CD163
CD163
IFN responses
IL‐10
breast cancer
tumor‐associated macrophages
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
09
2019
revised:
19
12
2019
accepted:
13
01
2020
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
23
2
2020
Statut:
epublish
Résumé
The accumulation of tumor-associated macrophages (TAMs) is correlated with poor clinical outcome, but the mechanisms governing their differentiation from circulating monocytes remain unclear in humans. Using multicolor flow cytometry, we evaluated TAMs phenotype in 93 breast cancer (BC) patients. Furthermore, monocytes from healthy donors were cultured in the presence of supernatants from dilacerated primary tumors to investigate their differentiation into macrophages (MΦ) We observed that high intra-tumor CD163-expressing TAM density is predictive of reduced survival in BC patients. Altogether, our results suggest that systemic factors skew BC patient blood monocytes towards a pro-metastatic profile, resulting in the accumulation of further polarised CD163
Identifiants
pubmed: 32082570
doi: 10.1002/cti2.1108
pii: CTI21108
pmc: PMC7017151
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1108Informations de copyright
© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Clin Dev Immunol. 2013;2013:806025
pubmed: 23762097
Nat Med. 2012 Aug;18(8):1224-31
pubmed: 22820642
Bioinformatics. 2010 Oct 1;26(19):2363-7
pubmed: 20688976
J Exp Med. 2018 Mar 5;215(3):859-876
pubmed: 29436396
Breast Cancer Res Treat. 2011 Aug;128(3):703-711
pubmed: 20842526
Clin Cancer Res. 2015 Aug 15;21(16):3794-805
pubmed: 25901081
Breast Cancer Res. 2015 Aug 05;17:101
pubmed: 26243145
Eur J Cancer. 2003 Mar;39(4):454-61
pubmed: 12751375
Immunol Res. 2013 Dec;57(1-3):86-98
pubmed: 24203436
Sci Rep. 2019 Aug 12;9(1):11634
pubmed: 31406165
N Engl J Med. 2000 Feb 24;342(8):525-33
pubmed: 10684910
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Bioinformatics. 2009 Jan 15;25(2):288-9
pubmed: 19033274
Breast Cancer Res. 2018 Dec 17;20(1):154
pubmed: 30558648
Nat Cell Biol. 2014 Aug;16(8):717-27
pubmed: 25082194
J Leukoc Biol. 2014 May;95(5):755-762
pubmed: 24436459
Cell Rep. 2018 May 1;23(5):1239-1248
pubmed: 29719241
Nat Rev Cancer. 2016 Mar;16(3):131-44
pubmed: 26911188
PLoS One. 2013;8(1):e54249
pubmed: 23342108
Immunity. 2017 Sep 19;47(3):582-596.e6
pubmed: 28930664
Carcinogenesis. 2014 Feb;35(2):424-31
pubmed: 24031027
J Exp Clin Cancer Res. 2006 Sep;25(3):365-72
pubmed: 17167977
Cell. 2018 Nov 1;175(4):1014-1030.e19
pubmed: 30343900
Int J Cancer. 2013 Aug 1;133(3):771-8
pubmed: 23389942
PLoS One. 2015 May 20;10(5):e0127028
pubmed: 25992611
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cell Immunol. 2013 Jan;281(1):51-61
pubmed: 23454681
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Genome Biol. 2014;15(12):550
pubmed: 25516281
Front Immunol. 2018 Sep 11;9:2028
pubmed: 30254632
Cancer Immunol Immunother. 2005 Jan;54(1):61-6
pubmed: 15693140
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Cancer Res. 2015 Oct 1;75(19):4063-73
pubmed: 26238785
J Leukoc Biol. 2014 Oct;96(4):619-31
pubmed: 24970861
N Engl J Med. 2005 Aug 25;353(8):793-802
pubmed: 16120859
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7119-24
pubmed: 19359475
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
Cancer Immunol Immunother. 2015 Feb;64(2):161-71
pubmed: 25314913
Cancer Res. 2001 Apr 1;61(7):3096-104
pubmed: 11306493
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Cancer Res. 2010 Oct 1;70(19):7465-75
pubmed: 20841473
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7265-70
pubmed: 21482760
Cancer Discov. 2011 Jun;1(1):54-67
pubmed: 22039576
J Exp Med. 1994 Nov 1;180(5):1999-2004
pubmed: 7964477
Oncoimmunology. 2015 Nov 10;5(3):e1100791
pubmed: 27141361
J Breast Cancer. 2019 Jan 02;22(1):38-51
pubmed: 30941232
Nat Immunol. 2003 Apr;4(4):380-6
pubmed: 12598895
Br J Cancer. 2003 Jun 2;88(11):1721-6
pubmed: 12771987
Cancer Res. 2016 Nov 15;76(22):6439-6442
pubmed: 28148676
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
J Exp Med. 2009 Jun 8;206(6):1327-37
pubmed: 19451266
J Leukoc Biol. 2012 Sep;92(3):673-82
pubmed: 22636320
Nat Rev Immunol. 2009 Apr;9(4):259-70
pubmed: 19282852
J Exp Med. 2019 Oct 7;216(10):2394-2411
pubmed: 31375534
Nat Cell Biol. 2019 Sep;21(9):1113-1126
pubmed: 31451770
NPJ Breast Cancer. 2016 Nov 02;2:16033
pubmed: 28721387
Int J Cancer. 2008 Aug 15;123(4):780-6
pubmed: 18506688
Oncogene. 2019 Jun;38(26):5158-5173
pubmed: 30872795
Blood. 2006 Mar 1;107(5):2112-22
pubmed: 16269622
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Blood. 2003 Jan 1;101(1):143-50
pubmed: 12393446
Endocr Relat Cancer. 2013 Oct 14;20(6):777-83
pubmed: 24016870
J Immunol. 2003 Oct 1;171(7):3385-93
pubmed: 14500632
Cancer Res. 2004 May 1;64(9):2941-55
pubmed: 15126324
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
Sci Rep. 2017 Feb 02;7:41686
pubmed: 28150715
Cancer Cell. 2014 Nov 10;26(5):623-37
pubmed: 25446896
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
Clin Cancer Res. 2019 Jul 1;25(13):3873-3886
pubmed: 30890553
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Immunity. 2014 Nov 20;41(5):815-29
pubmed: 25453823
BMC Genomics. 2015 Oct 19;16:814
pubmed: 26481321
J Immunol. 2012 Jun 1;188(11):5752-65
pubmed: 22547697
Sci Rep. 2019 Jul 29;9(1):10961
pubmed: 31358801
Int J Oncol. 2010 Oct;37(4):891-900
pubmed: 20811711
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Blood. 1998 Dec 15;92(12):4778-91
pubmed: 9845545
J Pathol. 2013 Mar;229(4):569-78
pubmed: 23192518